ES2120948T3 - Procedimiento y composiciones que mejoran los sintomas de la sepsis. - Google Patents

Procedimiento y composiciones que mejoran los sintomas de la sepsis.

Info

Publication number
ES2120948T3
ES2120948T3 ES90911485T ES90911485T ES2120948T3 ES 2120948 T3 ES2120948 T3 ES 2120948T3 ES 90911485 T ES90911485 T ES 90911485T ES 90911485 T ES90911485 T ES 90911485T ES 2120948 T3 ES2120948 T3 ES 2120948T3
Authority
ES
Spain
Prior art keywords
sepsis
symptoms
compositions
procedure
improve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90911485T
Other languages
English (en)
Inventor
Richard Ulevitch
Peter Tobias
Samuel D Wright
John C Mathison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Scripps Research Institute
Original Assignee
Rockefeller University
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University, Scripps Research Institute filed Critical Rockefeller University
Application granted granted Critical
Publication of ES2120948T3 publication Critical patent/ES2120948T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Two-Way Televisions, Distribution Of Moving Picture Or The Like (AREA)

Abstract

ESTA INVENCION DESCRIBE UN METODO PARA TRATAR LA SEPSIS QUE COMPRENDE EL ADMINISTRAR UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE MOLECULAS DE ANTICUERPO ANTI-CD14. SE DESCRIBE TAMBIEN UNA COMPOSICION TERAPEUTICA COMPRENDIENDO MOLECULAS DE ANTICUERPO ANTI-CD14 EN UN EXCIPIENTE FARMACEUTICAMENTE ACEPTABLE.
ES90911485T 1989-08-01 1990-07-30 Procedimiento y composiciones que mejoran los sintomas de la sepsis. Expired - Lifetime ES2120948T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38781789A 1989-08-01 1989-08-01

Publications (1)

Publication Number Publication Date
ES2120948T3 true ES2120948T3 (es) 1998-11-16

Family

ID=23531466

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90911485T Expired - Lifetime ES2120948T3 (es) 1989-08-01 1990-07-30 Procedimiento y composiciones que mejoran los sintomas de la sepsis.

Country Status (14)

Country Link
US (4) US5730980A (es)
EP (1) EP0485430B1 (es)
JP (1) JP2744130B2 (es)
AT (1) ATE171042T1 (es)
AU (1) AU645515B2 (es)
CA (1) CA2022429C (es)
DE (1) DE69032662T2 (es)
DK (1) DK0485430T3 (es)
ES (1) ES2120948T3 (es)
FI (1) FI920450A0 (es)
GR (1) GR1003164B (es)
IE (1) IE902770A1 (es)
PT (1) PT94869B (es)
WO (1) WO1991001639A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645515B2 (en) * 1989-08-01 1994-01-20 Rockefeller University, The Methods and compositions for ameliorating the symptoms of sepsis
DE4029227A1 (de) * 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
EP0634935A4 (en) * 1992-04-06 1996-01-31 North Shore Univ Hospital A NEW THERAPY OF SEPSIS BY MEANS OF A SOLUBLE FORM OF RECOMBINANT CD14 MYELOMONOCYTIC ANTIGEN.
EP0751962B1 (en) * 1993-05-28 2006-08-02 The Scripps Research Institute Methods for inhibiting cd14 mediated cell activation
WO1995000641A1 (en) * 1993-06-17 1995-01-05 Xoma Corporation Lipopolysaccharide binding protein derivatives
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5891618A (en) * 1994-01-24 1999-04-06 Xoma Corporation Method for quantifying LBP in body fluids
ES2255708T3 (es) 1994-09-16 2006-07-01 The Scripps Research Institute Uso de anticuerpos para bloquear los efectos de las bacterias gram-positivas y las micobacterias.
US5766593A (en) * 1994-12-30 1998-06-16 Amgen Inc. Anti-inflammatory CD14 peptides
EP0793677A1 (en) * 1994-12-30 1997-09-10 Amgen Inc. Anti-inflammatory cd14 polypeptides
WO1996032418A1 (en) * 1995-04-13 1996-10-17 Laboratoires Om S.A. Anti-cd14 antibodies for use in the induction of il-10 secretion
WO1997000081A1 (en) * 1995-06-19 1997-01-03 Goyert Sanna M A method for inhibiting bacteremia and bacterial dissemination
NZ332720A (en) * 1996-05-10 2000-07-28 Xoma Corp Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
AU736096B2 (en) * 1996-05-23 2001-07-26 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
US6093693A (en) * 1996-11-18 2000-07-25 The Wellesley Hospital Foundation B cell activation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US5990082A (en) * 1997-10-22 1999-11-23 Xoma Corporation Uses of lipopolysaccharide binding protein
WO1999039704A1 (en) * 1998-02-07 1999-08-12 British Biotech Pharmaceuticals Limited Antibacterial agents
PL345208A1 (en) * 1998-05-27 2001-12-03 Gemma Biotechnology Ltd The induction of antiobiotic proteins and peptides by lait/scd14-protein
US6974698B1 (en) * 1999-01-15 2005-12-13 The United States Of America As Represented By The Department Of Health And Human Services Methods for delivering biologically active molecules into cells
WO2001022085A1 (fr) * 1999-09-17 2001-03-29 Mochida Pharmaceutical Co., Ltd. Procede de mesure fractionnel de proteine de cd14 soluble
WO2002042333A1 (fr) * 2000-11-22 2002-05-30 Mochida Pharmaceutical Co., Ltd. Anticorps monoclonal anti-cd14 exerçant un effet d'inhibition de la fixation cd14/tlr
AU2002221099A1 (en) * 2000-12-08 2002-06-18 Takeda Chemical Industries Ltd. Combination drugs
JP2008522583A (ja) * 2002-06-14 2008-07-03 セントカー・インコーポレーテツド 修飾“ｓ”抗体
EP2266606B1 (en) * 2003-05-15 2014-09-10 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
WO2006093794A1 (en) * 2005-02-28 2006-09-08 Centocor, Inc. Heterodimeric protein binding compositions
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
CN103665168A (zh) 2005-06-03 2014-03-26 持田制药株式会社 抗cd14抗体融合蛋白质
WO2015140591A1 (en) * 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
AU2018255489B2 (en) * 2017-04-21 2024-06-13 Implicit Bioscience Limited CD 14 antagonist antibodies for treating neurodegenerative diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057598A (en) * 1983-05-06 1991-10-15 Centocor, Inc. Monoclonal antibodies reactive with endotoxin core
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US4834976A (en) * 1986-07-03 1989-05-30 Genetic Systems Corporation Monoclonal antibodies to pseudomonas aeruginosa flagella
AU645515B2 (en) * 1989-08-01 1994-01-20 Rockefeller University, The Methods and compositions for ameliorating the symptoms of sepsis

Also Published As

Publication number Publication date
US20020034509A1 (en) 2002-03-21
PT94869B (pt) 1997-04-30
WO1991001639A1 (en) 1991-02-21
US6495332B2 (en) 2002-12-17
US6297049B1 (en) 2001-10-02
FI920450A0 (fi) 1992-01-31
US5730980A (en) 1998-03-24
EP0485430A1 (en) 1992-05-20
JP2744130B2 (ja) 1998-04-28
AU645515B2 (en) 1994-01-20
PT94869A (pt) 1991-04-18
GR900100582A (el) 1991-12-30
EP0485430A4 (en) 1993-03-03
ATE171042T1 (de) 1998-10-15
JPH05501399A (ja) 1993-03-18
EP0485430B1 (en) 1998-09-16
US6045795A (en) 2000-04-04
CA2022429C (en) 1998-12-01
DE69032662T2 (de) 1999-03-11
CA2022429A1 (en) 1991-02-02
AU6146190A (en) 1991-03-11
DK0485430T3 (da) 1999-06-14
IE902770A1 (en) 1991-02-27
GR1003164B (el) 1999-07-05
DE69032662D1 (de) 1998-10-22

Similar Documents

Publication Publication Date Title
ES2120948T3 (es) Procedimiento y composiciones que mejoran los sintomas de la sepsis.
ES2062355T3 (es) Composicion farmaceutica que comprende loratadina, ibuprofeno y pseudoefedrina.
ES2149776T3 (es) Modulacion, inducida por un morfogeno, de la respuesta inflamatoria.
NO307645B1 (no) Anvendelse av probenecid i kombinasjon med en eksitatorisk aminosyre-antagonist for fremstilling av et farmasøytisk preparat
IT1281188B1 (it) Composizione per prevenire e trattare infiammazioni con immunoglobulina a.
DK0502925T3 (da) præparat til behandling af inflammatoriske tarmlidelser
DK1167354T3 (da) Racemisk huperzin A
IE802589L (en) Anti-inflammatory pharmaceutical composition containing¹rosmarinic acid
ES2139674T3 (es) Metodo para tratar la sintomatologia del sindrome premenstrual con vitamina d o vitamina d y calcio.
FI920139A0 (fi) Foerfaranden foer behandling och foerfindrande av autoimmun uveoretinitis hos daeggdjur.
ES555118A0 (es) Metodo de preparar medicamentos que incluyen un agente buscador de hueso y un inhibidor de anhidrasa carbonica, para impedir y curar enfermedades oseas.
ATE308994T1 (de) Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
MD1521F2 (en) Methods of thrombus forming inhibition, methods of treatment of thrombotic states, pharmaceutical compositions and kit for treatment of thrombotic states
DK0643585T3 (da) Anvendelsen af lipoprotein-associeret koagulationsinhibitor (LACI) til fremstilling af et lægemiddel til behandlingen af ak
NO921223L (no) Kombinasjonspreparat med antitrombotisk virkning
MX9302985A (es) Composicion farmaceutica para el tratamiento y la profilaxis de la ansiedad.
ES535091A0 (es) Procedimiento de obtencion de una fraccion de hidrocarburos a partir de cera de abeja.
ATE103890T1 (de) Neue acylaminosaeurederivate enthaltende arzneimittel und diaetetika.
AR007059A1 (es) Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto
ES2015349A6 (es) Metodo para producir anticuerpos inmunologicamente reactivos con angiogenina.
FR2422628A1 (fr) Esters benzylideniques et leur application en therapeutique
BG44873A3 (bg) Метод за получаване на кондензирани аs-триазини
IT8429520V0 (it) Super formula 8 speed - piloti e sponsor alla conquista del gran premio
ECSP972109A (es) Estimulacion de los mecanismos de defensa del huesped contra tumores

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 485430

Country of ref document: ES